The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases
Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus. Despite differing etiolog...
Gespeichert in:
| Veröffentlicht in: | Pharmacological reviews 2019-07, Vol.71 (3), p.345-382 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 382 |
|---|---|
| container_issue | 3 |
| container_start_page | 345 |
| container_title | Pharmacological reviews |
| container_volume | 71 |
| creator | Antonioli, Luca Blandizzi, Corrado Pacher, Pál Haskó, György |
| description | Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus. Despite differing etiologies, these diseases share common inflammatory pathways, which lead to damage in primary target organs and frequently to a plethora of systemic effects as well. The purinergic signaling complex comprising extracellular nucleotides and nucleosides and their receptors, the P2 and P1 purinergic receptors, respectively, as well as catabolic enzymes and nucleoside transporters is a major regulatory system in the body. The purinergic signaling complex can regulate the development and course of IMIDs. Here we provide a comprehensive review on the role of purinergic signaling in controlling immunity, inflammation, and organ function in IMIDs. In addition, we discuss the possible therapeutic applications of drugs acting on purinergic pathways, which have been entering clinical development, to manage patients suffering from IMIDs. |
| doi_str_mv | 10.1124/pr.117.014878 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6592405</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2246907068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-e67379871809c7b3f7187fd20d326376c5eb3f619c6e1140bca1a7a65215de043</originalsourceid><addsrcrecordid>eNpVkUFvGyEQhVGVqnHcHnuNOOayKSwL7F4iVU7SWHJUS3XPaMzO2hstiwtsJP_7UjmJmtMbmI_HjB4hXzm75rysvh1CVn3NeFXr-gOZcVnygrGan5EZY4IXqmn0ObmI8YllSNbyEzkXvBRSSTEjw2aPdD2FfsSw6y39dYwJHYVIga73EBxYP_jcgYFuIOww0c4HmvKrTUBIDsdEfUeXzk0jFo_Y9pCwpcuxG8A5SD4c6W0fESLGz-RjB0PELy86J7_v7zaLh2L188dy8X1VWFHrVKDSQje15jVrrN6KLle6a0vWilIJrazEfKl4YxVyXrGtBQ4aVN5ctsgqMSc3J9_DtHXY2jxjgMEcQu8gHI2H3rzvjP3e7PyzUbIpKyazwdWLQfB_JozJuD5aHAYY0U_RlGWlGqaZqjNanFAbfIwBu7dvODP_EsrnrNqcEsr85f-zvdGvkYi_9gKNhg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2246907068</pqid></control><display><type>article</type><title>The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Antonioli, Luca ; Blandizzi, Corrado ; Pacher, Pál ; Haskó, György</creator><contributor>Page, Clive</contributor><creatorcontrib>Antonioli, Luca ; Blandizzi, Corrado ; Pacher, Pál ; Haskó, György ; Page, Clive</creatorcontrib><description>Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus. Despite differing etiologies, these diseases share common inflammatory pathways, which lead to damage in primary target organs and frequently to a plethora of systemic effects as well. The purinergic signaling complex comprising extracellular nucleotides and nucleosides and their receptors, the P2 and P1 purinergic receptors, respectively, as well as catabolic enzymes and nucleoside transporters is a major regulatory system in the body. The purinergic signaling complex can regulate the development and course of IMIDs. Here we provide a comprehensive review on the role of purinergic signaling in controlling immunity, inflammation, and organ function in IMIDs. In addition, we discuss the possible therapeutic applications of drugs acting on purinergic pathways, which have been entering clinical development, to manage patients suffering from IMIDs.</description><identifier>ISSN: 0031-6997</identifier><identifier>ISSN: 1521-0081</identifier><identifier>EISSN: 1521-0081</identifier><identifier>DOI: 10.1124/pr.117.014878</identifier><identifier>PMID: 31235653</identifier><language>eng</language><publisher>United States: The American Society for Pharmacology and Experimental Therapeutics</publisher><subject>Animals ; Humans ; Inflammation - drug therapy ; Inflammation - immunology ; Inflammation - metabolism ; Molecular Targeted Therapy ; Purinergic Agonists - pharmacology ; Purinergic Antagonists - pharmacology ; Purines - immunology ; Purines - metabolism ; Receptors, Purinergic - immunology ; Receptors, Purinergic - metabolism ; Review ; Signal Transduction - drug effects</subject><ispartof>Pharmacological reviews, 2019-07, Vol.71 (3), p.345-382</ispartof><rights>U.S. Government work not protected by U.S. copyright.</rights><rights>U.S. Government work not protected by U.S. copyright 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-e67379871809c7b3f7187fd20d326376c5eb3f619c6e1140bca1a7a65215de043</citedby><cites>FETCH-LOGICAL-c387t-e67379871809c7b3f7187fd20d326376c5eb3f619c6e1140bca1a7a65215de043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31235653$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Page, Clive</contributor><creatorcontrib>Antonioli, Luca</creatorcontrib><creatorcontrib>Blandizzi, Corrado</creatorcontrib><creatorcontrib>Pacher, Pál</creatorcontrib><creatorcontrib>Haskó, György</creatorcontrib><title>The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases</title><title>Pharmacological reviews</title><addtitle>Pharmacol Rev</addtitle><description>Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus. Despite differing etiologies, these diseases share common inflammatory pathways, which lead to damage in primary target organs and frequently to a plethora of systemic effects as well. The purinergic signaling complex comprising extracellular nucleotides and nucleosides and their receptors, the P2 and P1 purinergic receptors, respectively, as well as catabolic enzymes and nucleoside transporters is a major regulatory system in the body. The purinergic signaling complex can regulate the development and course of IMIDs. Here we provide a comprehensive review on the role of purinergic signaling in controlling immunity, inflammation, and organ function in IMIDs. In addition, we discuss the possible therapeutic applications of drugs acting on purinergic pathways, which have been entering clinical development, to manage patients suffering from IMIDs.</description><subject>Animals</subject><subject>Humans</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Molecular Targeted Therapy</subject><subject>Purinergic Agonists - pharmacology</subject><subject>Purinergic Antagonists - pharmacology</subject><subject>Purines - immunology</subject><subject>Purines - metabolism</subject><subject>Receptors, Purinergic - immunology</subject><subject>Receptors, Purinergic - metabolism</subject><subject>Review</subject><subject>Signal Transduction - drug effects</subject><issn>0031-6997</issn><issn>1521-0081</issn><issn>1521-0081</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUFvGyEQhVGVqnHcHnuNOOayKSwL7F4iVU7SWHJUS3XPaMzO2hstiwtsJP_7UjmJmtMbmI_HjB4hXzm75rysvh1CVn3NeFXr-gOZcVnygrGan5EZY4IXqmn0ObmI8YllSNbyEzkXvBRSSTEjw2aPdD2FfsSw6y39dYwJHYVIga73EBxYP_jcgYFuIOww0c4HmvKrTUBIDsdEfUeXzk0jFo_Y9pCwpcuxG8A5SD4c6W0fESLGz-RjB0PELy86J7_v7zaLh2L188dy8X1VWFHrVKDSQje15jVrrN6KLle6a0vWilIJrazEfKl4YxVyXrGtBQ4aVN5ctsgqMSc3J9_DtHXY2jxjgMEcQu8gHI2H3rzvjP3e7PyzUbIpKyazwdWLQfB_JozJuD5aHAYY0U_RlGWlGqaZqjNanFAbfIwBu7dvODP_EsrnrNqcEsr85f-zvdGvkYi_9gKNhg</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Antonioli, Luca</creator><creator>Blandizzi, Corrado</creator><creator>Pacher, Pál</creator><creator>Haskó, György</creator><general>The American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201907</creationdate><title>The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases</title><author>Antonioli, Luca ; Blandizzi, Corrado ; Pacher, Pál ; Haskó, György</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-e67379871809c7b3f7187fd20d326376c5eb3f619c6e1140bca1a7a65215de043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Humans</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Molecular Targeted Therapy</topic><topic>Purinergic Agonists - pharmacology</topic><topic>Purinergic Antagonists - pharmacology</topic><topic>Purines - immunology</topic><topic>Purines - metabolism</topic><topic>Receptors, Purinergic - immunology</topic><topic>Receptors, Purinergic - metabolism</topic><topic>Review</topic><topic>Signal Transduction - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antonioli, Luca</creatorcontrib><creatorcontrib>Blandizzi, Corrado</creatorcontrib><creatorcontrib>Pacher, Pál</creatorcontrib><creatorcontrib>Haskó, György</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacological reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antonioli, Luca</au><au>Blandizzi, Corrado</au><au>Pacher, Pál</au><au>Haskó, György</au><au>Page, Clive</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases</atitle><jtitle>Pharmacological reviews</jtitle><addtitle>Pharmacol Rev</addtitle><date>2019-07</date><risdate>2019</risdate><volume>71</volume><issue>3</issue><spage>345</spage><epage>382</epage><pages>345-382</pages><issn>0031-6997</issn><issn>1521-0081</issn><eissn>1521-0081</eissn><abstract>Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus. Despite differing etiologies, these diseases share common inflammatory pathways, which lead to damage in primary target organs and frequently to a plethora of systemic effects as well. The purinergic signaling complex comprising extracellular nucleotides and nucleosides and their receptors, the P2 and P1 purinergic receptors, respectively, as well as catabolic enzymes and nucleoside transporters is a major regulatory system in the body. The purinergic signaling complex can regulate the development and course of IMIDs. Here we provide a comprehensive review on the role of purinergic signaling in controlling immunity, inflammation, and organ function in IMIDs. In addition, we discuss the possible therapeutic applications of drugs acting on purinergic pathways, which have been entering clinical development, to manage patients suffering from IMIDs.</abstract><cop>United States</cop><pub>The American Society for Pharmacology and Experimental Therapeutics</pub><pmid>31235653</pmid><doi>10.1124/pr.117.014878</doi><tpages>38</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6997 |
| ispartof | Pharmacological reviews, 2019-07, Vol.71 (3), p.345-382 |
| issn | 0031-6997 1521-0081 1521-0081 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6592405 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Animals Humans Inflammation - drug therapy Inflammation - immunology Inflammation - metabolism Molecular Targeted Therapy Purinergic Agonists - pharmacology Purinergic Antagonists - pharmacology Purines - immunology Purines - metabolism Receptors, Purinergic - immunology Receptors, Purinergic - metabolism Review Signal Transduction - drug effects |
| title | The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A40%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Purinergic%20System%20as%20a%20Pharmacological%20Target%20for%20the%20Treatment%20of%20Immune-Mediated%20Inflammatory%20Diseases&rft.jtitle=Pharmacological%20reviews&rft.au=Antonioli,%20Luca&rft.date=2019-07&rft.volume=71&rft.issue=3&rft.spage=345&rft.epage=382&rft.pages=345-382&rft.issn=0031-6997&rft.eissn=1521-0081&rft_id=info:doi/10.1124/pr.117.014878&rft_dat=%3Cproquest_pubme%3E2246907068%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2246907068&rft_id=info:pmid/31235653&rfr_iscdi=true |